NCT00577993 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients


Sponsors: M.D. Anderson Cancer Center Genentech	Phases: Phase III
Indications	Acronym:
Lymphoma
Age Groups: Child Adult Senior	Gender: Both
Names: Drug: Fludarabine Drug: Novantrone Drug: Decadron Drug: Rituximab Drug: Interferon Drug: Doxorubicin Drug: Vincristine Drug: Bleomycin Drug: Cyclophosphamide Drug: Etoposide Drug: Cisplatin Drug: Ara-C Drug: Methyl-Prednisolone Drug: Procarbazine Drug: Pr	Enrollment: 210

Additional information about NCT00577993.